FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeffrey Supko

Research Profile

Concepts & Ideas

Chemicals & Drugs

Procedures

Disorders

Co-author Network

Publications

TOP 3
Beata Holkova; Connie Honeycutt; Maciej Kmieciak; Renee M McGovern; Edward Brent Perkins; Viswanathan Ramakrishnan; Joel M Reid; John D Roberts; Heidi Sankala; Geoffrey I Shapiro; Ellen Shrader; Jeffrey G Supko; Mary Beth Tombes; Martha D Wellons; John Wright; Matthew M Ames; Austin Doyle; Steven Grant
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
David M Peereboom; Surasak Phuphanich; Myrna R Rosenfeld; Jeffrey G Supko; Xiaobu Ye; Manmeet S Ahluwalia; Stuart A Grossman; Sarah L Hilderbrand; Tom Mikkelsen; L Burt Nabors
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Lynda M Vrooman; Kristen E Stevenson; Jeffrey G Supko; Barbara L Asselin; Uma H Athale; Luis A Clavell; Harvey J Cohen; Suzanne E Dahlberg; Kara M Kelly; Jeffery L Kutok; Caroline Laverdière; Steven E Lipshultz; Bruno Michon; Donna Neuberg; Jane O'Brien; Mary V Relling; Stephen E Sallan; Marshall Schorin; Lewis B Silverman
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeffrey Supko (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Beata Holkova; Connie Honeycutt; Maciej Kmieciak; Renee M McGovern; Edward Brent Perkins; Viswanathan Ramakrishnan; Joel M Reid; John D Roberts; Heidi Sankala; Geoffrey I Shapiro; Ellen Shrader; Jeffrey G Supko; Mary Beth Tombes; Martha D Wellons; John Wright; Matthew M Ames; Austin Doyle; Steven Grant
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(7):1873-83.
2013: David M Peereboom; Surasak Phuphanich; Myrna R Rosenfeld; Jeffrey G Supko; Xiaobu Ye; Manmeet S Ahluwalia; Stuart A Grossman; Sarah L Hilderbrand; Tom Mikkelsen; L Burt Nabors
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Neuro-oncology 2013;15(4):490-6.
2013: Lynda M Vrooman; Kristen E Stevenson; Jeffrey G Supko; Barbara L Asselin; Uma H Athale; Luis A Clavell; Harvey J Cohen; Suzanne E Dahlberg; Kara M Kelly; Jeffery L Kutok; Caroline Laverdière; Steven E Lipshultz; Bruno Michon; Donna Neuberg; Jane O'Brien; Mary V Relling; Stephen E Sallan; Marshall Schorin; Lewis B Silverman
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(9):1202-10.
2013: Andrew X Zhu; Thomas A Abrams; Marek Ancukiewicz; Pankaj Bhargava; Lawrence S Blaszkowsky; Charles S Fuchs; Rakesh K Jain; Michelle Knowles; Nadine Jackson McCleary; Jeffrey A Meyerhardt; Alona Muzikansky; Eileen Regan; David P Ryan; Dushyant V Sahani; Susan Sheehan; Jeffrey G Supko; Eamala Vasudev; Dan G Duda
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(6):1557-66.
2013: Jethro Hu; Nadia Salem; Jeffrey G Supko; Patrick Y Wen; Lauren E Abrey; Jan Drappatz; Camilo E Fadul; Fred Hochberg
A phase II trial of oral gimatecan for recurrent glioblastoma.
Journal of neuro-oncology 2013;111(3):347-53.
2013: Brian M Wolpin; Andrew X Zhu; Thomas Abrams; Jill N Allen; Pankaj Bhargava; Lawrence S Blaszkowsky; Jennifer A Chan; Meaghan Elliot; Peter C Enzinger; Wolfram Goessling; Eunice L Kwak; Nadine J McCleary; Jeffrey A Meyerhardt; Kimmie Ng; Eileen Regan; Kaori Sato; Deborah Schrag; Jeffrey G Supko; Charles S Fuchs
Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.
The oncologist 2013;18(4):377-8.
2012: Sarah B Goldberg; C. Rebecca Suk Heist; Thomas J Lynch; Patricia O McCarthy; Alona Muzikansky; Joel W Neal; Jeffrey E Settleman; Sreenath Sharma; Alice T Shaw; Jeffrey G Supko; Jennifer S Temel; Subba R Digumarthy; Panos Fidias; Lecia V Sequist
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(10):1602-8.
2012: Limo Chen; Michael Chorev; Severine Denoyelle; Revital Yefidoff Freedman; Bertal H Aktas; Xiaoying He; Eihab Kabha; Rupam Sahoo; Jeffrey G Supko; Gerhard Wagner; Yibo Wang; Hongwei Yang; Nancy Zhang; Jose A Halperin
Tumor suppression by small molecule inhibitors of translation initiation.
Oncotarget 2012;3(8):869-81.
2012: David S Hong; Sergej Konoplev; Marina Konopleva; Donald Kufe; Razelle Kurzrock; Donald Lawrence; Hillard Lazarus; Colin J Meyer; James Mier; Aung Naing; Geoffrey I Shapiro; Jeffrey G Supko; Jennifer Wheler; Michael Andreeff; Joseph Paul Eder; Deborah A Ferguson; Xiaoying He; Bruce J Dezube
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(12):3396-406.
2012: Stuart A Grossman; Tom Mikkelsen; David M Peereboom; Myrna R Rosenfeld; Jeffrey G Supko; Xiaobu Ye; Serena Desideri
Phase I study of terameprocol in patients with recurrent high-grade glioma.
Neuro-oncology 2012;14(4):511-7.
2011: Ting Chen; Michael Chorev; Séverine Denoyelle; Jose A Halperin; Frederick Harbinski; Xiaoying He; Duygu Ozel; Yuan Qiao; Jeffrey G Supko; Nela Zvereva; Limo Chen; Bertal H Aktas
Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target.
Nature chemical biology 2011;7(9):610-6.
2011: Deepak Raina; Michio Kosugi; Rehan Ahmad; Govind Panchamoorthy; Hasan Rajabi; Maroof Alam; Takeshi Shimamura; Geoffrey I Shapiro; Jeffrey G Supko; Surender Kharbanda; Donald Kufe
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Molecular cancer therapeutics 2011;10(5):806-16.
2010: David M Peereboom; Jeffrey G Supko; Kathryn Carson; Tracy Batchelor; Surasak Phuphanich; Glenn Lesser; Tom Mikkelsen; Tom Mikkelson; Joy Fisher; Serena Desideri; Xiaoying He; Stuart A Grossman
A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
Journal of neuro-oncology 2010;100(2):261-8.
2010: Surasak Phuphanich; Jeffrey G Supko; Kathryn Carson; Stuart A Grossman; L Burt Nabors; Tom Mikkelsen; Glenn Lesser; Steve Rosenfeld; Serena Desideri; Jeffrey J Olson
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.
Journal of neuro-oncology 2010;100(1):95-103.
2010: Gregory H Bird; Navid Madani; Alisa F Perry; Amy M Princiotto; Jeffrey G Supko; Xiaoying He; Evripidis Gavathiotis; Joseph G Sodroski; Loren D Walensky
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(32):14093-8.
2010: Matthias Holdhoff; Jeffrey G Supko; Gary L Gallia; CHRISTINE HANN; David Bonekamp; Xiaobu Ye; Bing Cao; Alessandro Olivi; Stuart A Grossman
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.
Journal of neuro-oncology 2010;97(2):241-5.
2010: Lewis B Silverman; Jeffrey G Supko; Kristen E Stevenson; Christina Woodward; Lynda M Vrooman; Donna S Neuberg; Barbara L Asselin; Uma H Athale; Luis A Clavell; Peter Cole; Kara M Kelly; Caroline Laverdière; Bruno Michon; Marshall Schorin; Cindy L Schwartz; Jane E O'Brien; Harvey J Cohen; Stephen E Sallan
Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
Blood 2010;115(7):1351-3.
2010: Lynda M Vrooman; Jeffrey G Supko; Donna S Neuberg; Barbara L Asselin; Uma H Athale; Luis A Clavell; Kara M Kelly; Caroline Laverdière; Bruno Michon; Marshall Schorin; Harvey J Cohen; Stephen E Sallan; Lewis B Silverman
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
Pediatric blood & cancer 2010;54(2):199-205.
2009: Panos Fidias; Nathan A Pennell; Anthony L Boral; Geoffrey I Shapiro; Arthur T Skarin; Joseph P Eder; T Jesse Kwoh; Richard S Geary; Bruce E Johnson; Thomas J Lynch; Jeffrey G Supko
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(9):1156-62.
2009: Mark W Kieran; Jeffrey G Supko; Dana Wallace; Robert Fruscio; Tina Young Poussaint; Peter Phillips; Ian Pollack; Roger Packer; James M Boyett; Susan Blaney; Anu Banerjee; Russ Geyer; Henry Friedman; Stewart Goldman; Larry E Kun; Tobey Macdonald
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
Pediatric blood & cancer 2009;52(2):169-76.
2009: Andrew X Zhu; Neal Ready; jeffrey clark; Howard Safran; Antonino Amato; Nadia Salem; Silvia Pace; Xiaoying He; Nela Zvereva; Thomas J Lynch; David P Ryan; Jeffrey G Supko
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):374-81.
2009: Jaishri Blakeley; Jeffrey Olson; Stuart A Grossman; Xiaoying He; Jon D Weingart; Jeffrey G Supko
Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study.
Journal of neuro-oncology 2009;91(1):51-8.
2008: Stuart A Grossman; Kathryn Carson; Surasak Phuphanich; Tracy T Batchelor; David Peereboom; L Burt Nabors; Glenn Lesser; FREDERICK HAUSHEER; Jeffrey G Supko
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
Neuro-oncology 2008;10(4):608-16.
2008: Stuart A Grossman; Jeffrey Olson; Tracy Batchelor; David Peereboom; Glenn Lesser; Serena Desideri; Xiaobu Ye; Tarek Hammour; Jeffrey G Supko
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.
Neuro-oncology 2008;10(2):190-8.
2008: Xiu-Sheng Miao; Pengfei Song; Ronald E Savage; Caiyun Zhong; Rui-Yang Yang; Darin Kizer; Hui Wu; Erika Volckova; Mark A Ashwell; Jeffrey G Supko; Xiaoying He; Thomas C K Chan
Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; beta-lapachone) in whole blood.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(4):641-8.
2008: Eyal C Attar; Daniel J De Angelo; Jeffrey G Supko; Ferdinando D'Amato; David Zahrieh; Andres Sirulnik; Martha Wadleigh; Karen K Ballen; Steve McAfee; Kenneth B Miller; James Levine; Ilene Galinsky; Elizabeth G Trehu; David P Schenkein; Donna Neuberg; Richard M Stone; Philip C Amrein
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(5):1446-54.
2007: Ultan McDermott; Sreenath V Sharma; Lori Dowell; Patricia Greninger; Clara Montagut; Jennifer Lamb; Heidi Archibald; Raul Raudales; Angela Tam; Diana Lee; S Michael Rothenberg; Jeffrey G Supko; Raffaella Sordella; Lindsey Ulkus; A John Iafrate; Shyamala Maheswaran; Ching-Ni Njauw; Hensin Tsao; Lisa Drew; Jeff H Hanke; Xiao-Jun Ma; Mark G Erlander; Nathanael S Gray; Daniel A Haber; Jeffrey Settleman
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(50):19936-41.
2007: Jeffrey A Meyerhardt; jeffrey clark; Jeffrey G Supko; Joseph P Eder; Shuji Ogino; Clinton F Stewart; Ferdinando D'Amato; Janet Dancey; Peter C Enzinger; Andrew X Zhu; David P Ryan; Craig C Earle; Robert J Mayer; Ann Michelini; Kate Kinsella; Charlie S Fuchs
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Cancer chemotherapy and pharmacology 2007;60(5):661-70.
2007: Benson T Akingbemi; Tim D Braden; Barbara kemppainen; Karen D Hancock; Jessica D Sherrill; Sarah J Cook; Xiaoying He; Jeffrey G Supko
Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular Leydig cells in the adult rat.
Endocrinology 2007;148(9):4475-88.
2007: Serene S Srouji; Yanira L Pagán; Fernando D'Amato; Amsalu Dabela; Yarisie Jimenez; Jeffrey G Supko; Janet E Hall
Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome.
The Journal of clinical endocrinology and metabolism 2007;92(4):1347-52.
2007: Anna Berkenblit; Joseph P Eder; David P Ryan; Michael Seiden; Noriaki Tatsuta; Matthew L Sherman; Thomas A Dahl; Bruce J Dezube; Jeffrey G Supko
Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):584-90.
2006: David P Ryan; Bert O Neil; Jeffrey G Supko; Caio Rocha Lima; Elizabeth Dees; Leonard J Appleman; Jeffrey Clark; Panos Fidias; Robert Z Orlowski; Oscar Kashala; Joseph P Eder; James C Cusack
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Cancer 2006;107(11):2688-97.
2006: David P Ryan; Leonard J Appleman; Thomas J Lynch; Jeffrey G Supko; Panos Fidias; jeffrey clark; Mayer Fishman; Andrew X Zhu; Peter C Enzinger; Oscar Kashala; James C Cusack; Joseph P Eder
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Cancer 2006;107(10):2482-9.
2006: Stuart A Grossman; Kathryn Carson; Tracy T Batchelor; Glenn J Lesser; Tom Mikkelsen; Jane B Alavi; Surasak Phuphanich; Tarek Hammour; Joy D Fisher; Jeffrey G Supko
The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5174-81.
2006: Joseph P Eder; David P Ryan; Leonard J Appleman; Andrew X Zhu; Thomas A Puchalski; Xiaoying He; Daryl S Sonnichsen; Michael Cooper; John Wright; jeffrey clark; Jeffrey G Supko
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2006;58(1):107-16.
2006: Carolyn N Krasner; Maria Roche; Neil S Horowitz; Jeffrey G Supko; Susanna I Lee; Esther Oliva
Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.
The New England journal of medicine 2006;354(15):1615-25.
2006: Amber Klein; Xiaoying He; Maria Roche; Allison Mallett; Linda R Duska; Jeffrey G Supko; Michael Seiden
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
Gynecologic oncology 2006;100(1):205-9.
2005: Philip C Amrein; John R Clark; Jeffrey G Supko; Richard L Fabian; Chiu C Wang; A Dimitrios Colevas; Marshall R Posner; Daniel G Deschler; James William Rocco; Dianne M Finkelstein; James F McIntyre
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Cancer 2005;104(7):1418-27.
2005: Rocio Garcia-Carbonero; Jeffrey G Supko; ROBERT G MAKI; Judith Manola; David P Ryan; David Harmon; Thomas A Puchalski; G Goss; Michael Seiden; A Waxman; M Travis Quigley; T Lopez; M A Sancho; José Jimeno; Cecilia Guzman; George D Demetri
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5484-92.
2005: John R Goffin; Ian C Anderson; Jeffrey G Supko; Joseph P Eder; Geoffrey I Shapiro; Thomas J Lynch; Margaret A Shipp; Bruce E Johnson; Arthur T Skarin
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3417-24.
2005: Jaime Merchan; Deepa R Jayaram; Jeffrey G Supko; Xiaoying He; Glenn J Bubley; Vikas P Sukhatme
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
International journal of cancer. Journal international du cancer 2005;113(3):490-8.
2005: Loretta Lau; Jeffrey G Supko; Susan Blaney; Linda Hershon; Nita L Seibel; Mark Krailo; Wenchun Qu; David Malkin; Jose Jimeno; Mark Bernstein; Sylvain Baruchel
A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):672-7.
2005: Stuart A Grossman; Jane B Alavi; Jeffrey G Supko; Kathryn Carson; Regina Priet; F Andrew Dorr; John S Grundy; Jon T Holmlund
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
Neuro-oncology 2005;7(1):32-40.
2004: Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia Neal; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeffrey Settleman; Daniel A Haber
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
The New England journal of medicine 2004;350(21):2129-39.
2004: Rocio Garcia-Carbonero; Jeffrey G Supko; Judith Manola; Michael Seiden; David Harmon; David P Ryan; M Travis Quigley; P Merriam; J Canniff; G Goss; Ursula Matulonis; ROBERT G MAKI; T Lopez; Thomas A Puchalski; M A Sancho; J Gomez; Cecilia Guzman; José Jimeno; George D Demetri
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1480-90.
2004: David P Ryan; Joseph P Eder; Thomas Puchlaski; Michael Seiden; Thomas J Lynch; Charlie S Fuchs; Philip C Amrein; Daryl S Sonnichsen; Jeffrey G Supko; jeffrey clark
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2222-30.
2004: Joseph P Eder; Rocio Garcia-Carbonero; jeffrey clark; Jeffrey G Supko; Thomas A Puchalski; David P Ryan; Pamela Deluca; Antoinette J Wozniak; Angela Campbell; John Rothermel; Patricia M LoRusso
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
Investigational new drugs 2004;22(2):139-50.
2004: Andrew X Zhu; Thomas A Puchalski; Vincent P Stanton; David P Ryan; jeffrey clark; Steven Nesbitt; Olga Charlat; Patrick Kelly; Elaine Kreconus; Bruce A Chabner; Jeffrey G Supko
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Clinical colorectal cancer 2004;3(4):225-34.
2004: X He; Tracy T Batchelor; Stuart A Grossman; Jeffrey G Supko
Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;799(2):281-91.
2004: Tracy T Batchelor; Mark R Gilbert; Jeffrey G Supko; Kathryn Carson; L Burt Nabors; Stuart A Grossman; Glenn J Lesser; Tom Mikkelsen; Surasak Phuphanich
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
Neuro-oncology 2004;6(1):21-7.
2003: Jeffrey G Supko; Joseph P Eder; David P Ryan; Michael Seiden; Thomas J Lynch; Philip C Amrein; Donald Kufe; jeffrey clark
Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5178-86.
2003: Susana Campos; Ursula Matulonis; Richard T Penson; Hang Lee; Ross S Berkowitz; Linda R Duska; Arlan F Fuller; Kara S Wilson; Thomas A Puchalski; Jeffrey G Supko; Michael Seiden
Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors.
Gynecologic oncology 2003;90(3):610-8.
2003: Caroline Laverdiere; E Anders Kolb; Jeffrey G Supko; Richard Gorlick; Paul A Meyers; ROBERT G MAKI; Leonard H Wexler; George D Demetri; John Healey; Andrew G Huvos; Allen M Goorin; Rochelle Bagatell; Ana Ruiz-Casado; Cecilia Guzman; José Jimeno; David Harmon
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
Cancer 2003;98(4):832-40.
2003: Mark R Gilbert; Jeffrey G Supko; Tracy T Batchelor; Glenn J Lesser; Joy D Fisher; Steven Piantadosi; Stuart A Grossman
Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):2940-9.
2003: M Dror Michaelson; David P Ryan; Charlie S Fuchs; Jeffrey G Supko; Rocio Garcia-Carbonero; J Paul Eder; jeffrey clark
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
Cancer 2003;97(1):148-54.
2002: Thomas A Puchalski; David P Ryan; Rocio Garcia-Carbonero; George D Demetri; Leah Butkiewicz; David Harmon; Michael Seiden; ROBERT G MAKI; Luis Lopez-Lazaro; José Jimeno; Cecilia Guzman; Jeffrey G Supko
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Cancer chemotherapy and pharmacology 2002;50(4):309-19.
2002: Joseph P Eder; Jeffrey G Supko; jeffrey clark; Thomas A Puchalski; Rocio Garcia-Carbonero; David P Ryan; Larry N Shulman; Joann Proper; Moira Kirvan; Barbara Rattner; Susan Connors; Mary T Keogan; Milos J Janicek; William E Fogler; Lowell E Schnipper; Nancy Kinchla; Carolyn Sidor; Eric Phillips; Judah Folkman; Donald Kufe
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18):3772-84.
2002: Michael Seiden; Shu-Wing Ng; Jeffrey G Supko; David P Ryan; jeffrey clark; Thomas J Lynch; Kuan-Chun Huang; David Kwiatkowski; Arthur T Skarin; Joseph P Eder
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):691-7.
2002: Rocio Garcia-Carbonero; Jeffrey G Supko
Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):641-61.
2002: David P Ryan; Thomas A Puchalski; Jeffrey G Supko; David Harmon; ROBERT G MAKI; Rocio Garcia-Carbonero; Caroline Kuhlman; Jennifer Winkelman; Priscilla Merriam; Travis Quigley; José Jimeno; Judith Manola; George D Demetri
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
The oncologist 2002;7(6):531-8.
2001: Panos Fidias; Jeffrey G Supko; R Martins; A Boral; R Carey; M Grossbard; G Shapiro; Patricia Ostler; Joan Lucca; Bruce E Johnson; Arthur T Skarin; Thomas J Lynch
A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3942-9.
2001: Craig A Bunnell; Jeffrey G Supko; Joseph P Eder; jeffrey clark; Thomas J Lynch; Donald Kufe; Larry N Shulman
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.
Cancer chemotherapy and pharmacology 2001;48(5):347-55.
2001: Jeffrey G Supko; Rocio Garcia-Carbonero; Thomas A Puchalski; L Malspeis
Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
Cancer chemotherapy and pharmacology 2001;48(3):202-8.
2001: Richard T Penson; Jeffrey G Supko; Michael Seiden; Arlan F Fuller; R S Berkowitz; Annekathryn Goodman; Susana Campos; K M MacNeill; S Cook; Ursula Matulonis
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.
Cancer 2001;92(5):1156-67.
2001: Geoffrey I Shapiro; Jeffrey G Supko; A Patterson; Cathy Lynch; Joan Lucca; P F Zacarola; Alona Muzikansky; J J Wright; Thomas J Lynch; Barrett J Rollins
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1590-9.
2001: David P Ryan; Jeffrey G Supko; Joseph P Eder; Michael Seiden; George D Demetri; Thomas J Lynch; A J Fischman; J Davis; J Jimeno; jeffrey clark
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):231-42.
2000: R Ciordia; Jeffrey G Supko; M Gatineau; Tracy T Batchelor
Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing.
Current oncology reports 2000;2(5):445-53.
2000: LR Phillips; L Malspeis; E K Tubbs; Jeffrey G Supko
Characterization of a novel degradation product of 2,2'-dithiobis[N-isoleucylbenzamide], an inhibitor of HIV nucleocapsid protein zinc fingers.
Journal of pharmaceutical and biomedical analysis 2000;23(2-3):395-402.
2000: Jeffrey G Supko; Thomas J Lynch; jeffrey clark; Robert J Fram; L F Allen; R Velagapudi; Donald Kufe; Joseph P Eder
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.
Cancer chemotherapy and pharmacology 2000;46(4):319-28.
1999: Jeffrey G Supko; R V Nair; Michael Seiden; H Lu
Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatographic assay for paclitaxel in human plasma.
Journal of pharmaceutical and biomedical analysis 1999;21(5):1025-36.
1999: Linda R Duska; Richard T Penson; Jeffrey G Supko; D M Finkelstein; T Makastorsis; J Gallagher; K Borden; Annekathryn Goodman; Arlan F Fuller; N Nikrui; Michael Seiden
A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1299-305.
1999: Julie Sharpless; Jeffrey G Supko; KA Martin; JE Hall
Disappearance of endogenous luteinizing hormone is prolonged in postmenopausal women.
The Journal of clinical endocrinology and metabolism 1999;84(2):688-94.
1998: Jeffrey G Supko; J R Soglia; R V Nair
Assay for the quinocarmycin analog DX-52-1 in human plasma using high-performance liquid chromatography with automated column switching and low wavelength ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;714(2):341-53.
1998: LR Phillips; T L Wolfe; L Malspeis; Jeffrey G Supko
Analysis of brefeldin A and the prodrug breflate in plasma by gas chromatography with mass selective detection.
Journal of pharmaceutical and biomedical analysis 1998;16(8):1301-9.
1998: Joseph P Eder; Jeffrey G Supko; Thomas J Lynch; M Bryant; Evan Vosburgh; Larry N Shulman; G Xu; Donald Kufe
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):317-24.